Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 20/20 | 0.71 |
| ▸ | BRD2 | P25440 | 4/20 | 0.62 |
| ▸ | BRD3 | Q15059 | 2/20 | 0.60 |
| ▸ | DNER | Q8NFT8 | 1/20 | 0.60 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.58 |
| ▸ | TSPO | P30536 | 1/20 | 0.58 |
| ▸ | BRDT | Q58F21 | 3/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3211228 | 0.92 | BRD4 (0.72) | BRD4BRD2BRD3DNERADORA3 | |
| SCHEMBL23801064 | 0.92 | BRD4 (0.73) | BRD4BRD2BRD3DNERADORA3 | |
| SCHEMBL23321453 | 0.91 | BRD4 (0.72) | BRD4BRD2BRD3DNERADORA3 | |
| SCHEMBL23801161 | 0.90 | BRD4 (0.76) | BRD4BRD2BRD3DNERADORA3 | |
| SCHEMBL31548657 | 0.90 | BRD4 (0.84) | BRD4BRD2BRD3DNERADORA3 | |
| SCHEMBL23320790 | 0.90 | BRD4 (0.68) | BRD4BRD2BRD3DNERADORA3 | |
| SCHEMBL23321253 | 0.89 | BRD4 (0.70) | BRD4BRD2BRD3DNERADORA3 | |
| SCHEMBL23801110 | 0.89 | BRD4 (0.82) | BRD4BRD2BRD3DNERADORA3 | |
| SCHEMBL23801163 | 0.89 | BRD4 (0.69) | BRD4BRD2BRD3DNERADORA3 | |
| SCHEMBL23321117 | 0.88 | BRD4 (0.66) | BRD4BRD2BRD3DNERADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11542273-B2 | Amide compound having bet proteolysis-inducing action and medicinal application thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2023-01-03 | — | — | US | disclosed |
| US-20210284654-A1 | AMIDE COMPOUND HAVING BET PROTEOLYSIS-INDUCING ACTION AND MEDICINAL APPLICATION THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2021-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11542273-B2 | Amide compound having bet proteolysis-inducing action and medicinal application thereof | BET1, BRD4, PHKB | BRD4 2/4885BRD2 16/4885BRD3 7/4885 |
| US-20210284654-A1 | AMIDE COMPOUND HAVING BET PROTEOLYSIS-INDUCING ACTION AND MEDICINAL APPLICATION THEREOF | BET1, BRD4, PHKB | BRD4 2/4885BRD2 16/4885BRD3 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.